drugset / Trial / NCT02527434
Study of Tremelimumab in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors
Timeline
- Start
- 2015-11-02
- Primary completion
- 2018-02-17
- Completion
- 2023-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |